TWI767119B
Glufosfamide or its analogues have specific inhibitory effects on cells with specific genetic variations, more specifically, on cells with damaged DNA repair. The cell or tissue has at least one or more gene mutations of BRCA1, BRCA2, FANCD1, FANCD2, ATM, ATR, CHEK1, CHEK2, CTP, BARD1, BRIP1, PALB2,...
Gespeichert in:
| Hauptverfasser: | , , , |
|---|---|
| Format: | Patent |
| Sprache: | chi |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | DUAN, JIAN-XIN JUNG, DONALD T LI, AN-RONG MENG, FAN-YING |
| description | Glufosfamide or its analogues have specific inhibitory effects on cells with specific genetic variations, more specifically, on cells with damaged DNA repair. The cell or tissue has at least one or more gene mutations of BRCA1, BRCA2, FANCD1, FANCD2, ATM, ATR, CHEK1, CHEK2, CTP, BARD1, BRIP1, PALB2, RAD51D, RAD51C, RAD52, RAD54, RAD55, RAD57, FAM175, NBN, Rad50, MER11, p53, NBS1, XRS2, XRCC2, XRCC3, ERCC1, ERCC2, ERCC3, ERCC4, XRCC1, Ku80, MHS6, MGMT, PARP or ERCC5. The analogues refer to an ester obtained by esterification of one or more hydroxyl groups in the glufosfamide molecule with organic acids and inorganic oxyacids; an ester obtained by esterification of one or more hydroxyl groups in the glufosfamide molecule with an amino acid; the salt obtained by the reaction of a glufosfamide molecule with an acid. As such, the medical use of glufosfamide or its analogues in the treatment of tumors and cancer diseases in cancer patients with specific genetic variations is provided. |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_TWI767119BB</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>TWI767119BB</sourcerecordid><originalsourceid>FETCH-epo_espacenet_TWI767119BB3</originalsourceid><addsrcrecordid>eNrjZOAKCfc0NzM3NLR04mFgTUvMKU7lhdLcDApuriHOHrqpBfnxqcUFicmpeakl8QgNTsZEKAEADNMbjg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>TWI767119B</title><source>esp@cenet</source><creator>DUAN, JIAN-XIN ; JUNG, DONALD T ; LI, AN-RONG ; MENG, FAN-YING</creator><creatorcontrib>DUAN, JIAN-XIN ; JUNG, DONALD T ; LI, AN-RONG ; MENG, FAN-YING</creatorcontrib><description>Glufosfamide or its analogues have specific inhibitory effects on cells with specific genetic variations, more specifically, on cells with damaged DNA repair. The cell or tissue has at least one or more gene mutations of BRCA1, BRCA2, FANCD1, FANCD2, ATM, ATR, CHEK1, CHEK2, CTP, BARD1, BRIP1, PALB2, RAD51D, RAD51C, RAD52, RAD54, RAD55, RAD57, FAM175, NBN, Rad50, MER11, p53, NBS1, XRS2, XRCC2, XRCC3, ERCC1, ERCC2, ERCC3, ERCC4, XRCC1, Ku80, MHS6, MGMT, PARP or ERCC5. The analogues refer to an ester obtained by esterification of one or more hydroxyl groups in the glufosfamide molecule with organic acids and inorganic oxyacids; an ester obtained by esterification of one or more hydroxyl groups in the glufosfamide molecule with an amino acid; the salt obtained by the reaction of a glufosfamide molecule with an acid. As such, the medical use of glufosfamide or its analogues in the treatment of tumors and cancer diseases in cancer patients with specific genetic variations is provided.</description><language>chi</language><subject>HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><creationdate>2022</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20220611&DB=EPODOC&CC=TW&NR=I767119B$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,780,885,25564,76547</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20220611&DB=EPODOC&CC=TW&NR=I767119B$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>DUAN, JIAN-XIN</creatorcontrib><creatorcontrib>JUNG, DONALD T</creatorcontrib><creatorcontrib>LI, AN-RONG</creatorcontrib><creatorcontrib>MENG, FAN-YING</creatorcontrib><title>TWI767119B</title><description>Glufosfamide or its analogues have specific inhibitory effects on cells with specific genetic variations, more specifically, on cells with damaged DNA repair. The cell or tissue has at least one or more gene mutations of BRCA1, BRCA2, FANCD1, FANCD2, ATM, ATR, CHEK1, CHEK2, CTP, BARD1, BRIP1, PALB2, RAD51D, RAD51C, RAD52, RAD54, RAD55, RAD57, FAM175, NBN, Rad50, MER11, p53, NBS1, XRS2, XRCC2, XRCC3, ERCC1, ERCC2, ERCC3, ERCC4, XRCC1, Ku80, MHS6, MGMT, PARP or ERCC5. The analogues refer to an ester obtained by esterification of one or more hydroxyl groups in the glufosfamide molecule with organic acids and inorganic oxyacids; an ester obtained by esterification of one or more hydroxyl groups in the glufosfamide molecule with an amino acid; the salt obtained by the reaction of a glufosfamide molecule with an acid. As such, the medical use of glufosfamide or its analogues in the treatment of tumors and cancer diseases in cancer patients with specific genetic variations is provided.</description><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2022</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZOAKCfc0NzM3NLR04mFgTUvMKU7lhdLcDApuriHOHrqpBfnxqcUFicmpeakl8QgNTsZEKAEADNMbjg</recordid><startdate>20220611</startdate><enddate>20220611</enddate><creator>DUAN, JIAN-XIN</creator><creator>JUNG, DONALD T</creator><creator>LI, AN-RONG</creator><creator>MENG, FAN-YING</creator><scope>EVB</scope></search><sort><creationdate>20220611</creationdate><title>TWI767119B</title><author>DUAN, JIAN-XIN ; JUNG, DONALD T ; LI, AN-RONG ; MENG, FAN-YING</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_TWI767119BB3</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>chi</language><creationdate>2022</creationdate><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>DUAN, JIAN-XIN</creatorcontrib><creatorcontrib>JUNG, DONALD T</creatorcontrib><creatorcontrib>LI, AN-RONG</creatorcontrib><creatorcontrib>MENG, FAN-YING</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>DUAN, JIAN-XIN</au><au>JUNG, DONALD T</au><au>LI, AN-RONG</au><au>MENG, FAN-YING</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>TWI767119B</title><date>2022-06-11</date><risdate>2022</risdate><abstract>Glufosfamide or its analogues have specific inhibitory effects on cells with specific genetic variations, more specifically, on cells with damaged DNA repair. The cell or tissue has at least one or more gene mutations of BRCA1, BRCA2, FANCD1, FANCD2, ATM, ATR, CHEK1, CHEK2, CTP, BARD1, BRIP1, PALB2, RAD51D, RAD51C, RAD52, RAD54, RAD55, RAD57, FAM175, NBN, Rad50, MER11, p53, NBS1, XRS2, XRCC2, XRCC3, ERCC1, ERCC2, ERCC3, ERCC4, XRCC1, Ku80, MHS6, MGMT, PARP or ERCC5. The analogues refer to an ester obtained by esterification of one or more hydroxyl groups in the glufosfamide molecule with organic acids and inorganic oxyacids; an ester obtained by esterification of one or more hydroxyl groups in the glufosfamide molecule with an amino acid; the salt obtained by the reaction of a glufosfamide molecule with an acid. As such, the medical use of glufosfamide or its analogues in the treatment of tumors and cancer diseases in cancer patients with specific genetic variations is provided.</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | chi |
| recordid | cdi_epo_espacenet_TWI767119BB |
| source | esp@cenet |
| subjects | HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS |
| title | TWI767119B |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T23%3A55%3A06IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=DUAN,%20JIAN-XIN&rft.date=2022-06-11&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3ETWI767119BB%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |